DOCSLIB.ORG

National OTC Medicines List-2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
National OTC Medicines List-2018 National OTC Medicines List – First Edition 2018 NATIONAL OTC MEDICINES LIST First Edition 2018 Foreword According to the French National Agency for Medicines and Health Products Safety (ANSM), Over‐the‐ counter (OTC) drugs are medicines that are accessible to patients in pharmacies, based on criteria set to safeguard patients’ safety. FDA’s Center for Drug Evaluation and Research (CDER) regulates over‐the‐counter (OTC) which are drugs that have been found to be safe and appropriate for use without the supervision of a health care professional such as a physician, and they can be purchased by consumers without a prescription. Due to their therapeutic class, these medicines could be dispensed without physician’s intervention for diagnostic, treatment initiation or maintenance purposes. According to Arcle 43 of the Law No.367 issued in 1994 related to the pharmacy practice, and the amendment of Arcles 46 and 47 by Law No.91 issued in 2010, pharmacists do not have the right to dispense any medicine that is not requested through a unified prescription, unless the medicine is mentioned in a list which is established by the Orders of Pharmacists and Physicians In this regards, the Ministry of Public Health (MoPH) developed the National OTC list, presented it in a scientific, objective, reliable and accessible listingand issued by a Ministerial decision. At this stage, no “convenience size packaging” nor “restriction to a maximum dose” or a “maximum dose per day” or “length of treatment” were considered for some molecules to allow them to be classified as OTC. The list covers medicines that are intended to relief patients from minor to moderate symptoms for a determined period, and procured with the pharmacist’s assistance without the physician’s intervention. In developing the OTC Medicines List, reference was made to the French, UK, Switzerland, Canada, FDA and AESGP lists. hp://ansm.sante.fr/content/download/13055/158978/version/42/file/Medicaments‐Acces‐ Direct_Annexe‐1_Decembre‐2017.pdf http://www.aesgp.eu/ hps://www.swissmedic.ch/arzneimiel/00156/00221/00222/00230/index.html?lang=fr hps://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm10636 8.htm hp://www.sfda.gov.sa/ar/drug/search/Pages/drugdetails.aspx?did=4169&sm=human http://www.cpd‐pharma.ae/ https://www.pagb.co.uk/regulatory‐resources/otc‐medicines/ The National OTC Medicines List covers medicines, dosage forms, package sizes, drug strengths and other information registered at the MoPH. It is divided into sections based on the Anatomical Therapeutic Chemical (ATC) classification system. Each medication listing contains the following information: ATC code Brand or Generic status Ingredients Code Registration number Brand name Strength Presentation Form Agent Manufacturer Country of manufacturing Responsible Party Name Responsible Country Name The list will be updated regularly to include any new additions. The National OTC medicines List welcomes comments from healthcare professionals. Please send comments to: [email protected] ﻻئحة اﻷدوية المسموح ببيعھا دون وصفة طبية (OTC) من قبل المؤسسات الصيدﻻنية Responsible Party Brand name Strength Presentation Form Code Registration number B/G Ingredient ATC Agent Manufacturer Country Responsible Party Name Country Tablet, N-acetylcysteine - 600mg, Vitamin C - Salutas Pharma GmbH for ACC LONG 10 5143 23624/06 G R05CB01 Mersaco Germany effervescent 75mg Hexal AG Activated charcoal - 70mg, Papaverine Pharmamedic ACTICARBINE 42 Comprimé 2481 78773 G A03E Elerte France HCl - 14mg S.A.R.L. Pharmanet Suspension, United Arab ADOL 250mg/5ml 135ml 1341 208895/03 G Paracetamol - 250mg/5ml N02BE01 Drugstore Julphar alcohol free Emirates S.A.R.L. Pharmanet United Arab ADOL 500mg 24 Caplet 3740 78846/98 G Paracetamol - 500mg N02BE01 Drugstore Julphar Emirates S.A.R.L. Paracetamol - 325mg, Pseudoephedrine Pharmanet United Arab ADOL ALLERGY SINUS 24 Caplet 1342 974456/00 G HCl - 30mg, Chlorpheniramine maleate - N02BE51 Drugstore Julphar Emirates 2mg S.A.R.L. Paracetamol - 325mg, Pseudoephedrine Pharmanet United Arab ADOL COLD 24 Caplet 1343 974216/01 G HCl - 30mg, Dextromethorphan HBr - N02BE51 Drugstore Julphar Emirates 15mg S.A.R.L. Pharmanet United Arab ADOL EXTRA 24 Caplet 1709 973937/02 G Paracetamol - 500mg, Caffeine - 65mg N02BE51 Drugstore Julphar Emirates S.A.R.L. Pharmanet Paracetamol - 325mg, Diphenhydramine United Arab ADOL PM 24 Caplet 1710 973888/02 G N02BE51 Drugstore Julphar HCl - 25mg Emirates S.A.R.L. Droguerie ADVIL 200mg 50 Tablet, coated 1564 405436/00 B Ibuprofen - 200mg M01AE01 Pfizer Canada Inc Canada Canada Mercury S.A.L. Ibuprofen - 200mg, Pseudoephedrine Droguerie ADVIL COLD & SINUS 20 Caplet, coated 1575 405437/00 B M01AE51 Pfizer Canada Inc Canada Canada HCl - 30mg Mercury S.A.L. Droguerie ADVIL LIQUI-GELS 200mg 32 Capsule 5787 218732/10 B Ibuprofen - 200mg M01AE01 Pfizer Canada Inc Canada Canada Mercury S.A.L. AERIALLERG 0.5mg/ml 125ml Syrup 6986 97366/12 G Desloratadine - 0.5mg/ml R06AX27 Mapico S.A.R.L. Pharma International Co Jordan Pharma International Co Jordan 05/08/2018 1/30 Quality Assurance of Pharmaceutical Products ﻻئحة اﻷدوية المسموح ببيعھا دون وصفة طبية (OTC) من قبل المؤسسات الصيدﻻنية Responsible Party Brand name Strength Presentation Form Code Registration number B/G Ingredient ATC Agent Manufacturer Country Responsible Party Name Country Tablet, film AERIALLERG 5mg 30 7562 167742/11 G Desloratadine - 5mg R06AX27 Mapico S.A.R.L. Pharma International Co Jordan Pharma International Co Jordan coated Pharmanet United Arab ALBENDA 200mg 2 Tablet 1350 973998/02 G Albendazole - 200mg P02CA03 Drugstore Julphar Emirates S.A.R.L. Pharmanet United Arab ALBENDA 400mg 20ml Suspension 1351 973999/02 G Albendazole - 100mg/5ml P02CA03 Drugstore Julphar Emirates S.A.R.L. ALMIRAL 1% w/w 50g Gel 8411 166818/11 G Diclofenac sodium - 1% w/w D11AX18 New Allpharma Medochemie Ltd Cyprus Medochemie Ltd Cyprus Solution pour Pierre Fabre Medicament ALOPEXY 2% 60ml application 2755 974104/01 G Minoxidil - 20mg/ml D11AX01 Mersaco France Pierre Fabre Dermatologie France Production cutanee Solution pour Pierre Fabre Medicament ALOPEXY 2% 3 x 60ml application 7189 186282/13 G Minoxidil - 20mg/ml D11AX01 Mersaco France Pierre Fabre Dermatologie France Production cutanee Diphenhydramine HCl - 13.5mg/5ml, Expectorant Pharmanet Sodium citrate - 57mg/5ml, Ammonium United Arab AMYDRAMINE 120ml Syrup, sugar 1352 973940/02 G R06AA52 Drugstore Julphar chloride - 131.5mg/5ml, Menthol - Emirates free S.A.R.L. 1mg/5ml Lidocaine HCl - 1mg, Dequalinium HCl - ANGINOVA 20 Lozenge 3847 26814 G A01AB New Allpharma Spirig Pharm AG Switzerland Medinova AG Switzerland 0.25mg Lidocaine HCl - 100mg/100ml, Hydrocortisone acetate - 60mg/100ml, ANGINOVAG 10ml Aerosol 2576 20112 G Tyrothricin - 400mg/100ml, Dequalinium R02A Spephal S.A.L. Ferrer International SA Spain chloride - 100mg/100ml, β-Glycerrhetinic acid 60mg/100ml Valerian root dry extract - 200mg, Hop Macromed ARDEYSEDON NACHT 50 Tablet, coated 8345 34915/1 G N05CM09 Ardeypharm GmbH Germany Ardeypharm GmbH Germany Stobile - 68mg S.A.R.L. Macromed ARDEYSEDON NACHT 20 Tablet, coated 8346 34815/1 G Valerian root dry extract - N05CM09 Ardeypharm GmbH Germany Ardeypharm GmbH Germany S.A.R.L. Tablet, ASPICOT 100mg 100 4673 261087/97 G Acetylsalicylic acid - 100mg B01AC06 Pharmaline S.A.L. Pharmaline SAL Lebanon Pharmaline SAL Lebanon enteric coated 05/08/2018 2/30 Quality Assurance of Pharmaceutical Products ﻻئحة اﻷدوية المسموح ببيعھا دون وصفة طبية (OTC) من قبل المؤسسات الصيدﻻنية Responsible Party Brand name Strength Presentation Form Code Registration number B/G Ingredient ATC Agent Manufacturer Country Responsible Party Name Country Tablet, ASPICOT 100mg 30 4680 261088/97 G Acetylsalicylic acid - 100mg B01AC06 Pharmaline S.A.L. Pharmaline SAL Lebanon Pharmaline SAL Lebanon enteric coated Droguerie R. Tablet, ASPIRIN PROTECT 100mg 20 7004 97499/12 B Acetylsalicylic acid - 100mg B01AC06 Pharaon & Fils Bayer Bitterfeld GmbH Germany Bayer Consumer Care AG Switzerland enteric coated S.A.L. Droguerie R. ASPIRINE 0.3g 30 Tablet 7635 50114/1 B Acetylsalicylic acid - 300mg N02BA01 Pharaon & Fils Bayer Bitterfeld GmbH Germany Bayer Consumer Care AG Switzerland S.A.L. Droguerie R. ASPIRINE C Tablet, Acetylsalicylic acid - 400mg, Vitamin C - 10 7709 61014/1 B N02BA51 Pharaon & Fils Bayer Bitterfeld GmbH Germany Bayer Consumer Care AG Switzerland EFFERVESCENT effervescent 240mg S.A.L. Adenosine (triphosphate disodic ATEPADENE 30mg 30 Gélules 3126 973374/01 B M03C Spephal S.A.L. Mayoly Spindler France trihydrate) - 30mg Vaginal AZONIT 1% 40g 3485 195060/04 G Isoconazole nitrate - 10mg/g G01AF07 Mapico S.A.R.L. Pharma International Co Jordan Pharma International Co Jordan Cream Diflucortolone valerate - 1mg/g, AZONIT - D 20g Cream 759 208552/03 G D07XC04 Mapico S.A.R.L. Pharma International Co Jordan Pharma International Co Jordan Isoconazole nitrate - 10mg/g Dextrose monohydrate - 25g/l, Citrate - 6 Bottles x240ml 30mEq/ml, Chloride - 35mEq/ml, Pharmaceuticals Solutions Pharmaceuticals Solutions BABYLYTE Oral Solution 957 973719/02 G A07CA Pharmamed Saudi Arabia Saudi Arabia /Pack Potassium - 20mEq/ml, Sodium - Industry Ltd Industry Ltd 45mEq/ml BATRAFEN NAIL Sanofi Aventis Deutschland Sanofi Aventis Deutschland 3g Solution 2705 135376 B Ciclopirox - 8g/100g D01AE14 Mersaco Germany Germany LACQUER GmbH GmbH Nicotinamide - 50mg, Calcium Pantothenate - 25mg, Biotin - 0.15mg, Droguerie R. Dragenopharm Apotheker BECOZYM FORTE 20 Dragée 1369 3561 B Vitamin B12 - 10mcg, Vitamin
Load more

Recommended publications
  • Appendix a Common Abbreviations Used in Medication
    UNIVERSITY OF AMSTERDAM MASTERS THESIS Impact of Medication Grouping on Fall Risk Prediction in Elders: A Retrospective Analysis of MIMIC-III Critical Care Database Student: SRP Mentor: Noman Dormosh Dr. Martijn C. Schut Student No. 11412682 – SRP Tutor: Prof. dr. Ameen Abu-Hanna SRP Address: Amsterdam University Medical Center - Location AMC Department Medical Informatics Meibergdreef 9, 1105 AZ Amsterdam Practice teaching period: November 2018 - June 2019 A thesis submitted in fulfillment of the requirements for the degree of Master of Medical Informatics iii Abstract Background: Falls are the leading cause of injury in elderly patients. Risk factors for falls in- cluding among others history of falls, old age, and female gender. Research studies have also linked certain medications with an increased risk of fall in what is called fall-risk-increasing drugs (FRIDs), such as psychotropics and cardiovascular drugs. However, there is a lack of consistency in the definitions of FRIDs between the studies and many studies did not use any systematic classification for medications. Objective: The aim of this study was to investigate the effect of grouping medications at different levels of granularity of a medication classification system on the performance of fall risk prediction models. Methods: This is a retrospective analysis of the MIMIC-III cohort database. We created seven prediction models including demographic, comorbidity and medication variables. Medica- tions were grouped using the anatomical therapeutic chemical classification system (ATC) starting from the most specific scope of medications and moving up to the more generic groups: one model used individual medications (ATC level 5), four models used medication grouping at levels one, two, three and four of the ATC and one model did not include med- ications.
    [Show full text]
  • Appendix on Tariff Elimination Schedule for Mercosur
    Trade part of the EU-Mercosur Association Agreement Without Prejudice Disclaimer: In view of the Commission's transparency policy, the Commission is publishing the texts of the Trade Part of the Agreement following the agreement in principle announced on 28 June 2019. The texts are published for information purposes only and may undergo further modifications including as a result of the process of legal revision. However, in view of the growing public interest in the negotiations, the texts are published at this stage of the negotiations for information purposes. These texts are without prejudice to the final outcome of the agreement between the EU and Mercosur. The texts will be final upon signature. The agreement will become binding on the Parties under international law only after completion by each Party of its internal legal procedures necessary for the entry into force of the Agreement (or its provisional application). AR applied BR applied PY applied UY applied Mercosur Final NCM Description Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 01022911 Other bovine animals for breeding,pregnant or lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 01023911 Other buffalo for breeding, ex.
    [Show full text]
  • Central Valley Toxicology Drug List
    Chloroform ~F~ Lithium ~A~ Chlorpheniramine Loratadine Famotidine Acebutolol Chlorpromazine Lorazepam Fenoprofen Acetaminophen Cimetidine Loxapine Fentanyl Acetone Citalopram LSD (Lysergide) Fexofenadine 6-mono- Clomipramine acetylmorphine Flecainide ~M~ Clonazepam a-Hydroxyalprazolam Fluconazole Maprotiline Clonidine a-Hydroxytriazolam Flunitrazepam MDA Clorazepate Albuterol Fluoxetine MDMA Clozapine Alprazolam Fluphenazine Medazepam Cocaethylene Amantadine Flurazepam Meperidine Cocaine 7-Aminoflunitrazepam Fluvoxamine Mephobarbital Codeine Amiodarone Fosinopril Meprobamate Conine Amitriptyline Furosemide Mesoridazine Cotinine Amlodipine Methadone Cyanide ~G~ Amobarbital Methanol Cyclobenzaprine Gabapentin Amoxapine d-Methamphetamine Cyclosporine GHB d-Amphetamine l-Methamphetamine Glutethamide l-Amphetamine ~D~ Methapyrilene Guaifenesin Aprobarbital Demoxepam Methaqualone Atenolol Desalkylfurazepam ~H~ Methocarbamol Atropine Desipramine Halazepam Methylphenidate ~B~ Desmethyldoxepin Haloperidol Methyprylon Dextromethoraphan Heroin Metoclopramide Baclofen Diazepam Hexobarbital Metoprolol Barbital Digoxin Hydrocodone Mexiletine Benzoylecgonine Dihydrocodein Hydromorphone Midazolam Benzphetamine Dihydrokevain Hydroxychloroquine Mirtazapine Benztropine Diltiazem Hydroxyzine Morphine (Total/Free) Brodificoum Dimenhydrinate Bromazepam ~N~ Diphenhydramine ~I~ Bupivacaine Nafcillin Disopyramide Ibuprofen Buprenorphine Naloxone Doxapram Imipramine Bupropion Naltrexone Doxazosin Indomethacin Buspirone NAPA Doxepin Isoniazid Butabarbital Naproxen
    [Show full text]
  • Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K
    HANDBOOK OF Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K. Niazi CRC PRESS Boca Raton London New York Washington, D.C. Table of Contents PART I Regulatory and Manufacturing Guidance 1 Chapter 1 Current Good Manufacturing Practice Considerations in Liquid Manufacturing 3 I. Introduction 3 II. Facilities 3 III. Equipment 3 IV. Raw Materials 4 V. Compounding 4 VI. Microbiological Quality 4 VII. Oral Suspensions 5 VIII. Product Specifications 5 IX. Process Validation 5 X. Stability 5 XI. Packaging 6 Chapter 2 Stability Testing of New Drug Substances and Products 7 I. Introduction 7 II. Drug Substance 7 A. General Case 8 B. Drug Substances Intended for Storage in a Refrigerator 8 C. Drag Substances Intended for Storage in a Freezer 8 D. Drug Substances Intended for Storage below -20°C 9 HI. Drag Product 10 A. General Case •' B. Drag Products Packaged in Impermeable Containers 11 C. Drag Products Packaged in Semipermeable Containers 11 D. Drag Products Intended for Storage in a Refrigerator 12 E. Drag Products Intended for Storage in a Freezer 13 F. Drag Products Intended for Storage below -20"C 13 IV Glossary 14 References 1() Chapter 3 Container Closure Systems '7 I. Introduction '7 A. Definitions '7 B. Current Good Manufacturing Practice, the Consumer Product Safety Commission, and Requirements on Containers and Closures 17 C. Additional Considerations 17 II. Qualification and Quality Control of Packaging Components 18 A. Description 21 B. Information about Suitability 21 C. Stability Data (Packaging Concerns) 22 D. Inhalation Drag Products 23 E. Injection and Ophthalmic Drag Products 23 F.
    [Show full text]
  • The New Face of Drug Abuse: Impact on Your Children, Family, and Community
    The New Face of Drug Abuse: Impact on your Children, Family, and Community Patrick J. Sammon, Ph.D . [email protected] Impact of Prescription Drug Abuse: Illegal use of these drugs is responsible for multiple overdoses and fatalities Opiate addiction is blamed for causing a surge in crime: Robberies and break-ins at pharmacies Drug shoppers scamming doctors Harassments, assaults, and robberies of patients leaving drugstores Shoplifting and burglaries to support addiction Domestic violence and abuse Who’s at risk, who are the most vulnerable?: Adolescents - Sharp increase in 12 to 17 yr. olds and the 18 to 25 yr. olds Women - Increase rate of use in younger women Older adults - 17% of 60 + yr. olds may be affected by prescription drug abuse Why are Prescription Drugs so Popular? Legal, Easy to Obtain, Cheap and Safe & Non-addictive Legal: Perception that there is less legal risk than illicit drugs − Federal law does not distinguish between CI & CII drugs Easily obtainable: - From users, diverters, clinics, hospitals, Emergency Departments and practitioners and easy to steal Cheap: Low or no co-pay cost; may motivate people to use or sell PD’s Safer and Non-addictive: - Easily identity and less stigma than street drugs - Higher purity and less risky - Less HIV or hepatitis risk - Easier to use, no IV injecting but what about tolerance…and addiction! Commonly Misused and Abused Prescription & OTC Drugs Substance misuse is use of a drug that varies from a socially or medically accepted use. Substance abuse - any use of drugs that cause physical, psychological, economic, legal or social harm to the individual user or to others affected by the drug use's behavior.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Non-Pharmacologic Therapies and Airway Clearance Techniques in Bronchiectasis
    Division of Pulmonary, Critical Care and Sleep Medicine NON-PHARMACOLOGIC THERAPIES AND AIRWAY CLEARANCE TECHNIQUES IN BRONCHIECTASIS Ashwin Basavaraj, MD, FCCP Associate Director, NYU Bronchiectasis Program NTM Patient Education Program DC 11/24/2019 October 30, 2019 Financial Disclosure • Insmed - Consultant, Advisory Board (Active) • Hill-Rom – Consultant, Principal investigator on a clinical trial (Active) • COPD foundation grant on airway clearance 2 Division of Pulmonary, Critical Care and Sleep Medicine DC 11/24/2019 Case presentation • 66 year-old female with a history of prior pneumonia 15 years ago presents with productive cough. • She has mild shortness of breath. No fevers, no hemoptysis. She has gained two pounds over the year. • No other prior medical history, and currently not taking any medications • Initial workup including autoimmune serologies and quantitative immunoglobulin levels were negative. • You check AFB, bacterial and fungal sputum cultures. • She has 2 out 3 cultures positive for MAC. 3 Division of Pulmonary, Critical Care and Sleep Medicine DC 11/24/2019 4 Division of Pulmonary, Critical Care and Sleep Medicine DC 11/24/2019 What’s the next best step in management? A) Start 3 drug antibiotic therapy for MAC B) Initiate airway clearance with nebulized hypertonic saline and a positive expiratory pressure device C) Start antibiotics for MAC and initiate airway clearance D) Closely monitor without initiation of treatment 5 Division of Pulmonary, Critical Care and Sleep Medicine DC 11/24/2019 GOALS OF AIRWAY CLEARANCE Short term goals Long term goals • Provide more effective sputum • Reduce further airway damage by clearance that improves ventilation halting the vicious cycle • Reduce cough and breathlessness • Reduce pulmonary exacerbations • Improve quality of life O’Neill, et al.
    [Show full text]
  • Management of Breathlessness in Patients with Life Limiting Disease
    MANAGEMENT OF BREATHLESSNESS IN PATIENTS WITH LIFE LIMITING DISEASE Helen Armstrong Dr Helen Bonwick Dr Clare Jeffries Dr Martin Ledson Dr Kate Marley Mrs Sue Oakes CURRENT STANDARDS AND GUIDELINES • Current standards and guidleines • Literature review – pharmacological and non- pharmacological • Audit results • Proposed new standards and guidelines • Current management of cough Guidelines Non pharmacological options (Level 4 ) • These are important and should not be overlooked. They may be used alone or in conjunction with medication. • They include – Reassurance and explanation – Use of fan or cool air across face – Adequate positioning of the patient to aid breathing – Breathing exercises and relaxation training – Advice on modifying lifestyle – Acupuncture, aromatherapy and reflexology Guidelines Pharmacological options Benzodiazepines (Level 3) • Benzodiazepines may be useful especially if there is coexisting anxiety and/or fear. • Lorazepam is suggested for episodes of paroxysmal breathlessness. Dose: 0.5mg-1mg sublingually as required (max dose 4mg daily). • In patients unable to tolerate oral medication or those in the dying phase, subcutaneous Midazolam 2.5mg-5mg as required may be appropriate. If effective this can be incorporated into a 24hour subcutaneous infusion via syringe driver. Guidelines Nebulised Medication (Level 4)/(Level 1) NB: The first medication of any nebulised medication, including saline, must be monitored for adverse effect such as bronchospasm. • Nebulised non opioids – Nebulised sodium chloride 0.9% may help as a mucolytic. Consider trial for 24hours. Dose: 5ml via a nebuliser 4 hourly as required. – A trial of nebulised bronchodilator should be considered if there is evidence of airways obstruction (Level 4) commonly prescribed bronchdilators are Salbutamol and Ipratropium Bromide.
    [Show full text]
  • Bahrain-Pharma-1444108170.Pdf
    Fill Type of Competition S. No BP Brand Name Therapeutical Class Potency Generic Name/Composition Volume Dosage Name,company, retail price form Each 5 ml contents: Samol 120 ml Salbutamol Sulphate 2mg Salbutamol 1 Anti-Asthmatic agent (Bronchodilator) Each 5ml contains Acefylline piperazine 125mg Pifalin 100 ml Acefylline Piperazine 2 (125mg/5ml) Acefylline Piperazine 45mg, Diphenhydramine Dephicef 100 ml Acefylline Piperazine + Diphenhydramine 3 8mg/5ml Ammonium Chloride 100.00mg , Sodium Clomadrin 100 ml Citrate 60.00mg, Ephedrine HCl 7.00mg, Ammonium Chloride + Sodium Citrate + Ephedrine HCl + Chlorpheniramine Maleate 4 Chlorpheniramine Maleate 2.00mg/5ml Each 5 ml contents: Ambroxol HCl eq. to 100 ml Ambroxol 15mg 5 Ambrol Ambroxol HCl Each 5 ml contents: Ambroxol HCl eq. to Cough and Cold 100 ml Syrup 6 Ambroxol 30mg 7 Dextron 100 ml 15mg/5 ml Dextromethorphan Hbr 8 Gufosil 100 ml 100mg/5 ml Guaifenesin 9 Proligen 120 ml 1.25mg + 30mg/5 ml Triprolodin HCl + Pseudoephedrine HCl 10 Tripodil 120 ml 1.25mg + 30mg + 10mg/5 ml Triprolodin HCL + Pseudoephedrine HCl + Dextromethorphan Hbr 11 Tripogin 120 ml 1.25mg + 30mg + 100 mg/5 ml Triprolodin HCL + Pseudoephedrine HCl + Guaifenesin 12 Dexotrin 120 ml 1.25mg +10mg + 7.5mg + 50mg/5 ml Triprolodin HCL + Pseudoephedrine HCl + Dextromethorphan Hbr + Guaifenesin Wild cherry (Prunus serotina) + (myroxylon balsamum) + Mallow (Malva Sylvestris) + Welcosin 120 ml 60mg + 18.75mg + 7.5mg + 7.5mg / 5ml 13 Marshnallow (Althaea officinalis) 14 Ivosil 100 ml Each 5 ml contents: Ivy leaf 15 Hexobim 100 ml 4mg/5mlIvy leaves dried extract (4-8:1, 100%) 100 mg Bromhexine HCl Carbocisteine 2% and 5% (i.e.
    [Show full text]
  • Injectable Anesthesia in South American Camelids
    INJECTABLE ANESTHESIA IN SOUTH AMERICAN CAMELIDS Thomas Riebold DVM, Diplomate ACVAA Veterinary Teaching Hospital College of Veterinary Medicine Oregon State University Corvallis, Oregon 97331 INTRODUCTION Interest in llamas, and more recently in alpacas, as pets and as breeding and pack animals has led to increased demand for veterinary services for them. While they have some unique species characteristics regarding anesthesia, many of the principles and techniques used in food animal and equine anesthesia also apply to South American camelids. Except for differences in size, anesthetic management of alpacas and llamas is similar. Much like there are species differences between cattle, sheep, and goats in their response to xylazine, it does appear that alpacas require higher doses of sedatives, approximately 10-20%, to obtain the same response that lower doses of sedatives would obtain in llamas. PREANESTHETIC CONSIDERATIONS Consideration for preanesthetic preparation includes fasting, assessment of hematologic and blood chemistry values, venous catheterization, and estimation of bodyweight. The camelid has a stomach divided into three compartments. Therefore, potential complications similar to those of domestic ruminants, regurgitation and aspiration pneumonia, exist during anesthesia. Abdominal tympany as it occurs in anesthetized domestic ruminants does not appear to occur in anesthetized camelids. It is recommended that the animals be fasted 12-18 hours and deprived of water for 8-12 hours. In nonelective cases, this is often not possible and precautions should be taken to avoid aspiration of gastric fluid and ingesta. Fasting neonatal camelids is not advisable because hypoglycemia may result. As in other species, hematologic and blood chemistry values are determined before anesthesia.
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • Department of Health
    DEPARTMENT OF HEALTH National Drug Policy - Pharmaceutical Management Unit 50 National Formulary Committee Philippine National Drug Formulary EssentialEssential MedicinesMedicines ListList Volume I, 7th Edition ( 2008 ) Published by: The National Formulary Committee National Drug Policy ‐ Pharmaceutical Management Unit 50 DEPARTMENT OF HEALTH Manila, Philippines All rights reserved 2008 The National Formulary Committee National Drug Policy‐Pharmaceutical Management Unit 50 (NDP‐PMU 50) Department of Health San Lazaro Cmpd., Rizal Ave., Sta. Cruz, Manila, Philippines 1003 ISBN 978‐971‐91620‐7‐0 Any part or the whole book may be reproduced or transmitted without any alteration, in any form or by any means, with permission from DOH provided it is not sold commercially. ii PHILIPPINE NATIONAL DRUG FORMULARY Volume I, 7th Edition 2 0 0 8 Francisco T. Duque III, MD, MSc Secretary of Health Alexander A. Padilla Undersecretary of Health, Office for External Affairs Robert Louie P. So, MD Program Manager, NDP-PMU 50 Dennis S. Quiambao, MD Proj. Mgmt. Operating Officer & Coordinator (PMOOC) NDP-PMU 50 NATIONAL FORMULARY COMMITTEE Estrella B. Paje-Villar, MD, DTM & H Chairperson Jose M. Acuin, MD, MSc Alma L. Jimenez, MD Alejandro C. Baroque II, MD Marieta B. de Luna, MD Bu C. Castro, MD Nelia P. Cortes-Maramba, MD Dina V. Diaz, MD Yolanda R. Robles, PhD Pharm Mario R. Festin, MD, MS, MHPEd Isidro C. Sia, MD BFAD Representative SECRETARIAT Luzviminda O. Marquez, RPh, RMT Mary Love C. Victoria, RPh Michael D. Junsay, RPh Ermalyn M. Magturo iii Republic of the Philippines DEPARTMENT OF HEALTH OFFICE OF THE SECRETARY 2/F Bldg. 1, San Lazaro Cmpd., Rizal Avenue, Sta.
    [Show full text]